指南与共识肾血管病与高血压慢性肾脏病

欧洲肾脏协会对2023年欧洲高血压学会动脉高血压管理指南的肾脏病实践概要

A European Renal Association (ERA) synopsis for nephrology practice of the 2023 European Society of Hypertension (ESH) Guidelines for the Management of Arterial Hypertension.
指南 / 共识 · Nephrol Dial Transplant · 2024-01-01

2023年欧洲高血压学会(ESH)发布动脉高血压管理指南,欧洲肾脏协会(ERA)认可。本文由ESH和ERA专家撰写,概要总结指南中与肾脏病日常临床实践相关的章节,包括CKD在高血压分期和心血管风险分层中的作用、高血压介导的肾脏损害评估以及CKD患者高血压的整体管理,并列出若干与CKD患者相关的新推荐。

要点

  • 多数CKD患者诊室血压目标<130/80 mmHg,所有CKD患者避免<120/70 mmHg。
  • 难治性高血压:eGFR≥30用螺内酯,eGFR<30用氯噻酮。
  • CKD且eGFR≥20可考虑SGLT2抑制剂;特定CKD合并2型糖尿病蛋白尿患者可用非奈利酮。

核心结论

  • 2023 ESH指南包含多项与CKD患者高血压管理相关的新推荐,涉及血压目标、难治性高血压用药、SGLT2抑制剂、非奈利酮及肾血管病血运重建。

研究设计与样本

  • 本文为2023 ESH动脉高血压管理指南的概要,由ESH和ERA专家撰写,总结与肾脏病实践相关的章节。

主要发现

  • 指南推荐多数CKD患者诊室血压目标<130/80 mmHg,所有CKD患者反对目标<120/70 mmHg。
  • 难治性高血压患者eGFR≥30 mL/min/1.73 m2推荐螺内酯,eGFR<30推荐氯噻酮。
  • CKD且eGFR≥20 mL/min/1.73 m2推荐SGLT2抑制剂。
  • CKD合并2型糖尿病、蛋白尿、eGFR≥25 mL/min/1.73 m2且血钾<5.0 mmol/L推荐非奈利酮。
  • 动脉粥样硬化性肾血管病合并继发性高血压或高危表型且狭窄≥70%推荐血运重建。

关键数值与推荐

  • 诊室血压目标:多数CKD患者<130/80 mmHg,所有CKD患者避免<120/70 mmHg。
  • 难治性高血压:eGFR≥30 mL/min/1.73 m2用螺内酯,eGFR<30用氯噻酮。
  • SGLT2抑制剂:CKD且eGFR≥20 mL/min/1.73 m2。
  • 非奈利酮:CKD合并2型糖尿病、蛋白尿、eGFR≥25 mL/min/1.73 m2且血钾<5.0 mmol/L。
  • 肾血管病血运重建:动脉粥样硬化性肾血管病合并继发性高血压或高危表型且狭窄≥70%。

临床怎么用

  • 肾内科医生可依据本概要更新CKD患者高血压的血压目标及难治性高血压用药选择。
  • 对符合条件CKD患者考虑SGLT2抑制剂和非奈利酮的肾脏保护作用。
  • 筛查动脉粥样硬化性肾血管病,对狭窄≥70%且符合条件者评估血运重建。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In June 2023, the European Society of Hypertension (ESH) presented and published the new 2023 ESH Guidelines for the Management of Arterial Hypertension, a document that was endorsed by the European Renal Association (ERA). Following the evolution of evidence in recent years, several novel recommendations relevant to the management of hypertension in patients with chronic kidney disease (CKD) appeared in these Guidelines. These include recommendations for target office blood pressure (BP) <130/80 mmHg in most and against target office BP <120/70 mmHg in all patients with CKD; recommendations for use of spironolactone or chlorthalidone for patients with resistant hypertension with estimated glomerular filtration rate (eGFR) higher or lower than 30 mL/min/1.73 m2, respectively; use of a sodium-glucose cotransporter 2 inhibitor for patients with CKD and estimated eGFR ≥20 mL/min/1.73 m2; use of finerenone for patients with CKD, type 2 diabetes mellitus, albuminuria, eGFR ≥25 mL/min/1.73 m2 and serum potassium <5.0 mmol/L; and revascularization in patients with atherosclerotic renovascular disease and secondary hypertension or high-risk phenotypes if stenosis ≥70% is present. The present report is a synopsis of sections of the ESH Guidelines that are relevant to the daily clinical practice of nephrologists, prepared by experts from ESH and ERA. The sections summarized are those referring to the role of CKD in hypertension staging and cardiovascular risk stratification, the evaluation of hypertension-mediated kidney damage and the overall management of hypertension in patients with CKD.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Sarafidis P, Schmieder R, Burnier M, et al. A European Renal Association (ERA) synopsis for nephrology practice of the 2023 European Society of Hypertension (ESH) Guidelines for the Management of Arterial Hypertension. Nephrol Dial Transplant. 2024. PMID: 38365947. doi:10.1093/ndt/gfae041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。